Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma

Hematology/Oncology Clinics of North America

Volumn 29, Issue 4, 2015, Pages 761-776

  Rubinson, Douglas A ^a,b   Wolpin, Brian M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

FOLFIRINOX; Gemcitabine; Metastatic disease; Nab paclitaxel; Pancreatic cancer; Targeted therapy

Indexed keywords

ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DIARRHEA; DNA REPAIR; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; FEBRILE NEUTROPENIA; FUNCTIONAL STATUS; HUMAN; IMMUNE RESPONSE; METASTASIS POTENTIAL; MONOTHERAPY; NEUTROPENIA; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; THROMBOCYTOPENIA; ADENOCARCINOMA; DISEASE FREE SURVIVAL; METASTASIS; MORTALITY; PALLIATIVE THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM METASTASIS; PALLIATIVE CARE; PANCREATIC NEOPLASMS;

EID: 84938201940     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.04.012     Document Type: Review

References (59)

1. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Rahib L., Smith B.D., Aizenberg R., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014, 74(11):2913-2921.
3. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413.
4. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825.
5. Von Hoff D.D., Ervin T., Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369(18):1691-1703.
6. Hornick J.L., Lauwers G.Y., Odze R.D. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol 2005, 29(3):381-389.
7. Tempero M.A., Uchida E., Takasaki H., et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987, 47(20):5501-5503.
8. Humphris J.L., Chang D.K., Johns A.L., et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012, 23(7):1713-1722.
9. Boeck S., Haas M., Laubender R.P., et al. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 2010, 16(3):986-994.
10. Ueno H., Okada S., Okusaka T., et al. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000, 59(4):296-301.
11. Szkandera J., Stotz M., Absenger G., et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 2014, 110(1):183-188.
12. Yachida S., White C.M., Naito Y., et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res 2012, 18(22):6339-6347.
13. Biankin A.V., Waddell N., Kassahn K.S., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491(7424):399-405.
14. Huang P., Chubb S., Hertel L.W., et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51(22):6110-6117.
15. Grunewald R., Abbruzzese J.L., Tarassoff P., et al. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991, 27(4):258-262.
16. Gelibter A., Malaguti P., Di Cosimo S., et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005, 104(6):1237-1245.
17. Poplin E., Feng Y., Berlin J., et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27(23):3778-3785.
18. Poplin E., Wasan H., Rolfe L., et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 2013, 31(35):4453-4461.
19. Berlin J.D., Catalano P., Thomas J.P., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002, 20(15):3270-3275.
20. Cunningham D., Chau I., Stocken D.D., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27(33):5513-5518.
21. Herrmann R., Bodoky G., Ruhstaller T., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007, 25(16):2212-2217.
22. Ueno H., Ioka T., Ikeda M., et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013, 31(13):1640-1648.
23. Colucci G., Labianca R., Di Costanzo F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010, 28(10):1645-1651.
24. Heinemann V., Quietzsch D., Gieseler F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24(24):3946-3952.
25. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23(15):3509-3516.
26. Rocha Lima C.M., Green M.R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22(18):3776-3783.
27. Abou-Alfa G.K., Letourneau R., Harker G., et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006, 24(27):4441-4447.
28. Oettle H., Richards D., Ramanathan R.K., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005, 16(10):1639-1645.
29. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
30. Kindler H.L., Niedzwiecki D., Hollis D., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010, 28(22):3617-3622.
31. Van Cutsem E., Vervenne W.L., Bennouna J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009, 27(13):2231-2237.
32. Rougier P., Riess H., Manges R., et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer 2013, 49(12):2633-2642.
33. Kindler H.L., Ioka T., Richel D.J., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011, 12(3):256-262.
34. Goncalves A., Gilabert M., Francois E., et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012, 23(11):2799-2805.
35. Kindler H.L., Richards D.A., Garbo L.E., et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012, 23(11):2834-2842.
36. Philip P.A., Benedetti J., Corless C.L., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010, 28(22):3605-3610.
37. Ueda S., Ogata S., Tsuda H., et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004, 29(1):e1-8.
38. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966.
39. Wacker B., Nagrani T., Weinberg J., et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007, 13(13):3913-3921.
40. Van Cutsem E., Li C.P., Nowara E., et al. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer 2014, 111(11):2067-2075.
41. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359(17):1757-1765.
42. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23(25):5900-5909.
43. Heinemann V., Vehling-Kaiser U., Waldschmidt D., et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013, 62(5):751-759.
44. da Cunha Santos G., Dhani N., Tu D., et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010, 116(24):5599-5607.
45. Boeck S., Jung A., Laubender R.P., et al. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. J Gastroenterol 2013, 48(4):544-548.
46. Gourgou-Bourgade S., Bascoul-Mollevi C., Desseigne F., et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013, 31(1):23-29.
47. Mahaseth H., Brutcher E., Kauh J., et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013, 42(8):1311-1315.
48. Gunturu K.S., Yao X., Cong X., et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013, 30(1):361.
49. Neuzillet C., Tijeras-Raballand A., Cros J., et al. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013, 32(3-4):585-602.
50. Neesse A., Frese K.K., Chan D.S., et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 2014, 63(6):974-983.
51. Zhang Y., Hochster H.S., Stein S., et al. Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity. ASCO Meeting Abstracts 2014, 32(3_suppl):344.
52. Zaniboni A., Bertocchi P., Abeni C., et al. Gemcitabine plus nab-paclitaxel as second line and beyond for metastatic pancreatic cancer (MPC): A single institution retrospective analysis. ASCO Meeting Abstracts 2014, 32(15_suppl):e15202.
53. Oettle H., Riess H., Stieler J.M., et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014, 32(23):2423-2429.
54. Gill S., Ko Y.-J., Cripps M.C., et al. PANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). ASCO Meeting Abstracts 2014, 32(15_suppl):4022.
55. Von Hoff D., Li C.P., Wang-Gillam A., et al. O-0003NAPOLI-1: randomized phase 3 study of mm-398 (nal-iri), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy. Ann Oncol 2014, 25(suppl 2):ii105-ii106.
56. Hurwitz H., Uppal N., Wagner S.A., et al. A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC). ASCO Meeting Abstracts 2014, 32(15_suppl):4000.
57. Bramhall S.R., Schulz J., Nemunaitis J., et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87(2):161-167.
58. Van Cutsem E., van de Velde H., Karasek P., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004, 22(8):1430-1438.
59. Kulke M.H., Blaszkowsky L.S., Ryan D.P., et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007, 25(30):4787-4792.